Robust Revenue GrowthAlembic's 50.8% year-over-year revenue gain demonstrates durable commercial momentum across formulations and generics. Sustained high revenue growth improves scale economics, funds R&D and manufacturing capacity, and strengthens multi-quarter revenue visibility for strategic reinvestment.

Very Low Leverage / Strong Capital StructureExtremely low debt and a 93.4% equity ratio provide financial flexibility and low solvency risk. This durable balance sheet supports funding of regulatory timelines, capital expenditures and product launches without heavy external financing, preserving operational resilience.

High Gross And Operating MarginsRobust gross and operating margins reflect efficient manufacturing and a favorable product mix (FDFs and APIs). Structural margin strength supports sustained cash generation, pricing power versus peers and the ability to invest in brands and pipeline, enhancing long-term competitiveness.

Bears Say

Net Profit Margin Likely Driven By One-offsAnomalous 140% net margin attributed to non-recurring gains undermines the reliability of current profitability metrics. If those one-time items reverse, reported earnings and ROE may materially drop, reducing long-term earnings predictability and complicating planning for sustained shareholder returns.

Weak Cash ConversionOperating cash converts only 28% of net income and free cash flow only 11%, indicating earnings quality issues. Persistently low cash conversion constrains real financing capacity for capex, dividends or debt reduction and increases sensitivity to any downturn once non-recurring gains fade.

Dependence On Generics Approvals And LaunchesSignificant exposure to international generics ties medium-term growth to successful regulatory approvals and competitive launches. Delays, failed filings, or loss of share in regulated markets would structurally reduce revenue visibility and make future growth lumpy and execution-dependent.

Alembic Limited News

Alembic Limited Opens Special Window for Share Transfer Re-lodgement

Alembic Limited ( ($IN:ALEMBICLTD) ) has issued an announcement. Alembic Limited has announced a special window for the...

5M ago

Alembic Limited Updates Registrar Contact Details

Alembic Limited ( ($IN:ALEMBICLTD) ) has issued an announcement. Alembic Limited announced a change in the email and...

11M ago

ALEMBICLTD FAQ

What was Alembic Limited’s price range in the past 12 months?

Alembic Limited lowest stock price was ₹78.00 and its highest was ₹125.70 in the past 12 months.

What is Alembic Limited’s market cap?

Alembic Limited’s market cap is ₹20.40B.

When is Alembic Limited’s upcoming earnings report date?

Alembic Limited’s upcoming earnings report date is May 07, 2026 which is in 50 days.

How were Alembic Limited’s earnings last quarter?

Alembic Limited released its earnings results on Feb 12, 2026. The company reported ₹2.342 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.342.

Is Alembic Limited overvalued?

According to Wall Street analysts Alembic Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Limited pay dividends?

Alembic Limited pays a Annually dividend of ₹2.4 which represents an annual dividend yield of 2.36%. See more information on Alembic Limited dividends here

What is Alembic Limited’s EPS estimate?

Alembic Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alembic Limited have?

Alembic Limited has 256,781,830 shares outstanding.

What happened to Alembic Limited’s price movement after its last earnings report?

Alembic Limited reported an EPS of ₹2.342 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.726%.

Which hedge fund is a major shareholder of Alembic Limited?

Currently, no hedge funds are holding shares in IN:ALEMBICLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Limited

Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). It operates through API and Real Estate segments. The company is also involved in the construction of residential and commercial real estate projects; provision of project management and marketing consultancy services; and leasing of commercial properties. In addition, it operates co-generation plants with a total capacity of 11 MW; and wind power plants with a total capacity of 5 MW. The company also exports its products. Alembic Limited was founded in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Limited.